Selexys is a pharmaceutical company that developed a platform of Selectin Inhibition Technology consisting of therapies that target P-selectin glycoprotein ligand-1 (PSGL-1) and P-selectin to treat pain among those with sickle cell disease.

Year Founded: 2005

Year Partnered: 2009

Category: Biotech/Pharma

Fund: Accelerate, Oklahoma Seed Capital Fund  

   Acquired in 2017 by Novartis